Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC2695
Trial ID NCT04894435
Altered gene adenovirus|lipid nanoparticle
TherapyS
Treatment Therapeutic gene
Co-treatment vaccine
HLAAdult, Older_Adult
PhasePhase2
Recruitment statusActive, Not Recruiting
TitleImmunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic? RNA therapy mRNA vaccine BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax;MedicagoCovifenz "UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US;NULL
Year2021
CountryCanada

Clinical Result

in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19
in vivo
Administration route COVID-19

Relationship Graph

Overview of Knowledge Graph